FDA creates faster way to access over-the-counter naloxone products to treat opioid overdoses

The following is cross-posted from our Optum Insights—Government Affairs blog The U.S. Food and Drug Administration (FDA) recently established a more rapid path for pharmaceutical companies to add over-the-counter (OTC) naloxone products to the market to increase access to naloxone – a life-saving medication used for the emergency treatment of opioid-related overdose – and help … Read moreFDA creates faster way to access over-the-counter naloxone products to treat opioid overdoses

Lyrica® generic delayed until summer 2019 and Pfizer to increase drug prices

This is a cross-post from our Optum Insights blog. The U.S. Food and Drug Administration’s (FDA) recent decision to grant pediatric exclusivity for Lyrica® ― as it may be used as an adjunctive therapy for partial onset seizures in pediatric epilepsy patients ― extends the period of market exclusivity in the U.S. by an additional … Read moreLyrica® generic delayed until summer 2019 and Pfizer to increase drug prices